



Universiteit
Leiden
The Netherlands

Apo-calypse now? Apolipoprotein profiling to reduce residual cardiovascular disease

Reijnders, E.

Citation

Reijnders, E. (2025, October 30). *Apo-calypse now?: Apolipoprotein profiling to reduce residual cardiovascular disease.*


Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from:

Note: To cite this publication please use the final published version (if applicable).

APPENDICES



Nomenclature

Nederlandse samenvatting

Oral presentations at conferences

Teaching opportunities

Honors and awards

Publications

Curriculum Vitae

Dankwoord

NOMENCLATURE

4S	Scandinavian Simvastatin Survival Study
AA	arachidonic acid
ABCA1	ATP-binding cassette transporter A1
ACC	acetyl-CoA carboxylase
ACCORD	Action To Control Cardiovascular Risk In Diabetes
ACS	acute coronary syndrome
ADP	adenosine diphosphate
AF	arterial fibrillation
AFCAPS/TexCAPS	Air Force/Texas Coronary Atherosclerosis Prevention Study
AI	artificial intelligence
AIM-HIGH	Atherothrombosis Intervention In Metabolic Syndrome With Low HDL/High Triglycerides And Impact On Global Health Outcomes
AKI	acute kidney injury
AMI	acute myocardial infarction
ANGPTL	angiopoietin-like protein
Apo	apolipoprotein
APPROACH	A Study Of Volanesorsen (Formerly IONIS-ApoCIIIrx) In Patients With Familial Chylomicronemia Syndrome
ARBITER-2	Arterial Biology For The Investigation Of The Treatment Effects Of Reducing Cholesterol
ASCVD	atherosclerotic cardiovascular disease
ASO	antisense oligonucleotide
ATP	adenosine triphosphate
AUC	area under the receiver operating characteristic curve
BMI	body mass index
BNP	brain natriuretic peptide
CABG	coronary artery bypass graft
CAD	coronary artery disease
CANTOS	Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
CARAT	CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial
CCTA	coronary computed tomography angiography
CETP	cholesterol ester transfer protein
CHD	coronary heart disease
CHIP	clonal hematopoiesis of indeterminate potential
CIRT	Cardiovascular Inflammation Reduction Trial

CKD	chronic kidney disease
CM	chylomicron
COLCOT	Colchicine Cardiovascular Outcomes Trial
COMPASS	Rivaroxaban For The Prevention Of Major Cardiovascular Events In Coronary Or Peripheral Artery Disease
CRP	C-reactive protein
CV	cardiovascular
CV	coefficient of variation
CVD	cardiovascular disease
DAPT	dual antiplatelet therapy
DART	diet and reinfarction trial
DHA	docosahexaenoic acid
DPI	dual pathway inhibition
EAS	European Atherosclerosis Society
EFLM	European Federation of Clinical Chemistry and Laboratory Medicine
EMA	European Medicine Agency
Endo	endogenous
eNOS	endothelial nitric oxide synthase
ER	endoplasmic reticulum
ESC	European Society of Cardiology
EURICA	European Study Of Cardiovascular Risk
FA	fatty acid
FAI	fat attenuation index
FAIR	Findable, Accessible, Interoperable, and Reusable
FCS	familial chylomicronemia syndrome
FDA	Food & Drug Administration
FFA	free fatty acids
FH	familial hypercholesterolemia
FIELD	Fenofibrate Intervention And Event Lowering In Diabetes
FMD-J	Flow-Mediated Dilatation – Japan
FOURIER	Further Cardiovascular Outcomes Research With PCSK9 Inhibition In Subjects With Elevated Risk
GalNAc	N-acetylgalactosamine
GLP-1 RA	glucagon-like peptide-1 receptor agonist
GPIHBP1	glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein-1
HbA1c	hemoglobin A1c

HDL	high-density lipoprotein
HDL-c	high-density lipoprotein cholesterol
HL	hepatic lipase
HMG-CoA	hydroxymethylglutaryl CoA (HMG-CoA)
HRP	high-risk plaque
hsCRP	high sensitivity C-reactive protein
HSPG	heparan sulfate proteoglycan
HTG	hypertriglyceridemia
ICAM	intercellular adhesion molecules
IDL	intermediate-density lipoprotein
IHD	ischemic heart disease
IL	interleukin
ILLUMINATE	A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease
IMPROVE-IT	Improved Reduction Of Outcomes: Vytorin Efficacy International Trial
IMT	Intima-media thickness
iNOS	inducible nitric oxide synthase
INTERHEART	Effect Of Potentially Modifiable Risk Factors Associated With Myocardial Infarction In 52 Countries
IQC	internal quality control
IS	internal standard
IVDR	In Vitro Diagnostic Medical Devices Regulation
IVUS	intravascular ultrasound
JUPITER	Justification For The Use Of Statins In Prevention: An Intervention Trial Evaluating Rosuvastatin
LA	lipoprotein apheresis
LCAT	lecithin–cholesterol acyltransferase
LC-MS/MS	liquid chromatography tandem mass spectrometry
LDL	low-density lipoprotein
LDL-C	low-density lipoprotein cholesterol
LDLR	low-density lipoprotein receptor
LIMS	laboratory information management system
LMF1	lipase maturation factor-1
LoDoCo	Low-Dose Colchicine
LOF	loss of function
Lp(a)	lipoprotein(a)

Lp(a)HORIZON	Assessing The Impact Of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) On Major Cardiovascular Events In Patients With Cardiovascular Disease
LPL	lipoprotein lipase
LRP1	LDL receptor-related protein 1
LXR	liver X receptor
mAb	monoclonal antibody
MACCE	major adverse cardiac and cerebrovascular events
MACE	major adverse cardiac events
MetS	metabolic syndrome
MI	myocardial infarction
MINOCA	myocardial infarction with non-obstructive coronary arteries
MMP-12	metalloproteinase-12
MS	mass spectrometry
MTP	mitochondrial triglyceride transfer protein
NADPH	nicotinamide adenine dinucleotide phosphate (reduced)
NCP1L1	Niemann-Pieck C1-like1 protein
NFK β	nuclear factor kappa-light-chain-enhancer of activated B cells
NHANES	National Health And Nutrition Examination Survey
NLRP3	nucleotide-binding leucine-rich repeat receptor family pyrin domain containing 3
NMR	nuclear magnetic resonance
NO	nitric oxide
OCEAN(a)	Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction
OxPL	oxidized phospholipids
P5	predictive, preventive, personalized, participatory, psychocognitive
PAR	population attributable risk
PCI	percutaneous coronary intervention
PCOS	polycystic ovary syndrome
PCSK9	proprotein convertase subtilisin/kexin type 9
PEGASUS-TIMI 54	Prevention Of Cardiovascular Events In Patients With Prior Heart Attack Using Ticagrelor Compared To Placebo On A Background Of Aspirin–Thrombolysis In Myocardial Infarction 54
PLA2	phospholipase A2
PLG	plasminogen
PM	particulate matter
PPAR	peroxisome proliferator-activated receptors
PPC	polyene phosphatidylcholine

PREDIMED	Primary Prevention Of Cardiovascular Disease With A Mediterranean Diet
PRIME	Prospective Epidemiological Study of Myocardial Infarction
PROMINENT	Pemafibrate To Reduce Cardiovascular Outcomes By Reducing Triglycerides In Patients With Diabetes
PROVE-IT	Pravastatin Or Atorvastatin Evaluation And Infection Therapy
PROVE-IT-TIMI 22	The Pravastatin Or Atorvastatin Evaluation And Infection Therapy – Thrombolysis In Myocardial Infarction 22
QC	quality control
QMS	quality management system
R3I	Residual Risk Reduction Initiative
RAS	renin aldosterone system
RCT	randomized controlled trials
REDUCE-IT	Reduction Of Cardiovascular Events With Icosapent Ethyl–Intervention Trial
REVERSAL	Reversal Of Atherosclerosis With Aggressive Lipid Lowering
RNS	reactive nitrogen species
ROS	reactive oxygen species
SATURN	Statins Use In Intracerebral Hemorrhage Patient
sdLDL	small dense LDL
SGLT2i	sodium/glucose cotransporter 2 inhibitor
SIL	stable isotope-labelled
siRNA	small interfering RNA
SNP	single nucleotide polymorphism
SOLID-TIMI 52	The Stabilization Of Plaques Using Darapladib-Thrombolysis In Myocardial Infarction 52
SOP	standard operating procedure
SPIRE1/SPIRE2	The Evaluation Of Bococizumab (Pf-04950615;Rn316) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects
sPLA	secretory phospholipase A2
SR-B1	scavenger receptor class B type 1
SSS	system suitability sample
STABILITY	Stabilization Of Atherosclerotic Plaque By Initiation Of Darapladib Therapy
T1DM	type 1 diabetes mellitus
T2DM	type 2 diabetes mellitus
TC	total cholesterol
TEa	total allowable error
TG	triglycerides
TGRL	triglyceride-rich lipoprotein

TIMI-22	Pravastatin or Atorvastatin Evaluation and Infection Therapy
TMAO	trimethylamine N-oxide
TTP	total testing process
VCAM-1	vascular cell adhesion protein 1
VDLR	very-low-density lipoprotein receptor
VISTA-16	Varespladib And Cardiovascular Events In Patients With An Acute Coronary Syndrome 16
VLDL	very low-density lipoprotein
VTE	venous thromboembolism
WC	waist circumference
WHR	waist-to-hip ratio
ZEUS	A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation